| Trial ID # | NCT02799095; ARTISTRY-1 |
| Phase | I/II |
| Drug Class | Immunotherapy: Checkpoint Inhibitors/PD-1 |
| Drug Name | Pembrolizumab |
| Alternate Drug Names | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 |
| Drugs in Trial | Nemvaleukin alfa, Pembrolizumab |
| Eligible Participant | Advanced solid tumors |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, DoR, evaluated per RECIST |
| Efficacy | ALKS 4230: 36 patients, median 3 prior therapies (1-8), 1 ovarian ALKS 4230+Pem: 14 ovarian, median 5 prior therapies (2-11) |
| Conclusion | Pembrolizumab with Nemvaleukin alfa (ALKS 4230) is well tolerated with encouraging clinical benefit |
| Reference | Boni V et al. ARTISTRY-1: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors. J Clin Oncol (2021) 39 (suppl 15; abstr 2513) Boni V et al. Poster Slide from SGO 2022 presentation; scientific plenary III, abstract 229 Vaishampayan UN et al. Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1. J Clin Oncol 40, 2022 (suppl 16; abstr 2500) Vaishampayan UN et al. Slide from presentation |